Q2 FY25 Activities Report and Appendix 4C

Archer Materials Limited is pleased to provide its Quarterly Activities Report and Appendix 4C for the quarter ended 31 December 2024.

Key Highlights

• Launch of the TMR sensor project, where Archer will create bespoke sensors using its quantum expertise for industrial applications.
• Archer is about to commence work to optimise the TMR sensor design and engage with potential customers, potentially bringing forward revenue opportunities while it continues 12CQ quantum development.
• Fabricated a smaller Biochip gFET design through its foundry partner, a reduction of 97%, to reduce cost and improve foundry readiness.
• Moved closer to feasibility stages and improved testing accuracy for the Biochip’s detection of chronic kidney disease.
• Improved the control of the 12CQ quantum project by creating new device architecture which achieved the “Coulomb Blockade” phenomenon at room temperature.
• Improved readout of the 12CQ quantum project by extending the spin coherence lifetimes for both its carbon nanosphere material and novel manufacturable carbon films, along with bolstering the films’ sample-to-sample reproducibility.
• Strong cash position to fund activities with $16.8 million and no debt, supported by a A$2.1 million cash rebate from the Australian Federal Government’s Research and Development Tax Incentive program

Commenting on the Q1 FY25 activities, Greg English, Executive Chairman of Archer, said:

“Archer is continuing to develop the Biochip with a focus on the testing of chronic kidney disease of the Biochip, continued advancement with the 12CQ quantum project, and the launch of a new technology vertical in quantum-based TMR sensors.

“Leveraging Archer’s expertise in quantum mechanics, the Company will develop specialised TMR sensors for customers, which is expected to open a new part of the market for industrial applications and, potentially, an earlier revenue stream for Archer.

“We have successfully miniaturised the Biochip gFET to make it cheaper for customers and manufacturing, while preparing it for the foundry once developed. The Biochip team also improved the operation, processing, and design of the gFET sensors and moved it towards the feasibility stages of product development. This all helps bring the Biochip closer to the at-home testing of chronic kidney disease.

“We made considerable progress with the 12CQ project by building a new device architecture and fabrication process to observe key quantum electrical behaviour. This work helps move the team’s research forward in terms of control and room temperature functionality.

“Archer has a solid runway to bring these technologies to market, with the people and balance sheet in place to support the growth.”

Click here to view the full announcement